LEASE ASSIGNMENT & ASSUMPTIONLease Assignment & Assumption • March 8th, 2021 • Fulgent Genetics, Inc. • Services-medical laboratories • Texas
Contract Type FiledMarch 8th, 2021 Company Industry JurisdictionWHEREAS, by Service Center Lease Agreement (the "Lease") dated June 17, 2020, TEN-VOSS, LTD, "Landlord" or “Lessor”, leased MEDSCAN LABORATORIES INC. hereinafter “Tenant” or “Lessee”, those certain premises at 8560 Katy Freeway, Suite 200, Houston, Texas 77024.
SUBLEASE AGREEMENTSublease Agreement • March 8th, 2021 • Fulgent Genetics, Inc. • Services-medical laboratories • Texas
Contract Type FiledMarch 8th, 2021 Company Industry JurisdictionThis SUBLEASE AGREEMENT (this “Sublease”) is entered into as of July 1st, 2020 (the “Effective Date”), between Medscan Laboratory (“Tenant”) and Fulgent Genetics (“Subtenant”), with reference to the following:
COMMERCIAL LEASE ADDENDUM #1Commercial Lease Agreement • March 8th, 2021 • Fulgent Genetics, Inc. • Services-medical laboratories
Contract Type FiledMarch 8th, 2021 Company IndustryThis is addendum to the Commercial Lease Agreement signed on February 1, 2018 by E & E Plaza LLC ("Lessor") and Fulgent Therapeutics LLC ("Lessee"). This document modifies the Commercial Lease Agreement as described below.
EMPLOYMENT AGREEMENTEmployment Agreement • March 8th, 2021 • Fulgent Genetics, Inc. • Services-medical laboratories • California
Contract Type FiledMarch 8th, 2021 Company Industry JurisdictionThis EMPLOYMENT AGREEMENT (the “Agreement”), dated March 8, 2021, is by and among Fulgent Therapeutics LLC, a California limited liability company (the “Company”), Fulgent Genetics, Inc., a Delaware corporation (“HoldCo”) and Jian Xie (“Executive”).
SEVERANCE AGREEMENTSeverance Agreement • March 8th, 2021 • Fulgent Genetics, Inc. • Services-medical laboratories • California
Contract Type FiledMarch 8th, 2021 Company Industry JurisdictionThis SEVERANCE AGREEMENT (the “Agreement”), dated March 8, 2021, is by and among Fulgent Therapeutics LLC, a California limited liability company (the “Company”), Fulgent Genetics, Inc., a Delaware corporation (“HoldCo”) and Jian Xie (“Executive”).